We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Positive Results Signal New Lease for Exelixis’ Cancer Drug
Positive Results Signal New Lease for Exelixis’ Cancer Drug
Exelixis’ Cometriq improved patient outcomes in a pivotal Phase 3 trial for metastatic kidney cancer — signaling new life for the drug, which failed another study last fall.